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Abstract
Objective: Low serum 25(OH)D levels are associated with cardiovascular risk factors, and also predict future myocardial
infarction (MI), type 2 diabetes (T2DM), cancer and all-cause mortality. Recently several single nucleotide polymorphisms
(SNPs) associated with serum 25-hydroxyvitamin D (25(OH)D) level have been identified. If these relations are causal one
would expect a similar association between these SNPs and health.
Methods: DNA was prepared from subjects who participated in the fourth survey of the Tromsø Study in 1994–1995 and
who were registered with the endpoints MI, T2DM, cancer or death as well as a randomly selected control group. The
endpoint registers were complete up to 2007–2010. Genotyping was performed for 17 SNPs related to the serum 25(OH)D
level.
Results: A total of 9528 subjects were selected for genetic analyses which were successfully performed for at least one SNP
in 9471 subjects. Among these, 2025 were registered with MI, 1092 with T2DM, 2924 with cancer and 3828 had died. The
mean differences in serum 25(OH)D levels between SNP genotypes with the lowest and highest serum 25(OH)D levels
varied from 0.1 to 7.8 nmol/L. A genotype score based on weighted risk alleles regarding low serum 25(OH)D levels was
established. There was no consistent association between the genotype score or individuals SNPs and MI, T2DM, cancer,
mortality or risk factors for disease. However, for rs6013897 genotypes (located at the 24-hydroxylase gene (CYP24A1)) there
was a significant association with breast cancer (P,0.05).
Conclusion: Our results do not support nor exclude a causal relationship between serum 25(OH)D levels and MI, T2DM,
cancer or mortality, and our observation on breast cancer needs confirmation. Further genetic studies are warranted,
particularly in populations with vitamin D deficiency.
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Introduction
Vitamin D is an ancient hormone with indisputable importance
in calcium and bone metabolism. The vitamin D receptor (VDR)
is a nuclear receptor localised in cells in a number of organs
indicating important functions also in extra-skeletal tissues [1].
Thus, in previous reports from the Tromsø Study we have
found low serum 25-hydroxyvitamin D (25(OH)D) levels (which is
the vitamin D metabolite used to evaluate a subject’s vitamin D
status) to be strongly related to hypertension [2], obesity [3],
elevated glycated haemoglobin (HbA1c) [4] and an unfavourable
serum lipid profile [5]. In line with this we have found low serum
25(OH)D levels to be associated with the risk of developing type 2
diabetes mellitus (T2DM) [6] as well as with increased all-cause
mortality [7]. Similar observations have been reported from other
studies [8,9], and the serum 25(OH)D levels have also been
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associated with cancer [10]. Accordingly, the serum 25(OH)D
level appears to be an important risk factor for disease in general.
However, whether there is a causal relation between low serum
25(OH)D and disease is uncertain and awaits the results of
properly performed randomized clinical trials (RCT).
Intake of vitamin D and sun exposure are major determinants of
the serum 25(OH)D level, but cannot fully explain differences in
serum 25(OH)D between individuals [11]. Based on family and
twin studies it has been estimated that more than 50% of the
variability can be ascribed to genetic factors [12], and recently
several single nucleotide polymorphisms (SNPs) related to serum
25(OH)D have been identified [13,14]. These SNPs, where the
minor allele frequencies vary between 16 and 40%, appear as
important for the serum 25(OH)D level as the effect of vitamin D
supplementation and nearly as important as the effect of season
[13]. Accordingly, if the serum 25(OH)D level is causally related to
health, one would expect that subjects with polymorphisms
associated with low serum 25(OH)D levels would be more prone
to disease than subjects with presumably more favourable
polymorphisms.
The Tromsø Study is a longitudinal epidemiological population
health study with repeated surveys conducted at 6–7 years
intervals [15]. In the fourth survey performed in 1994–1995,
blood samples for preparation of DNA were collected in close to
27 000 subjects. The participants are followed-up with registration
of incident myocardial infarction (MI), T2DM, cancer and death,
and we therefore had the opportunity to test if SNPs in the vitamin
D system are related to hard endpoints as well as cardiovascular
disease (CVD) risk factors. However, the study did not provide
consistent evidence for such relations.
Materials and Methods
The Tromsø study
The Tromsø Study, conducted by the University of Tromsø in
cooperation with the National Health Screening Service, is a
longitudinal population-based multipurpose study focusing on
lifestyle related diseases. The fourth survey was performed in
1994–1995, the fifth in 2001–2002 and the sixth in 2007–2008;
27 158, 8130 and 12984 subjects attended, respectively (Table 1)
[15,16].
Definition of T2DM endpoints
Possible cases of T2DM were identified through self-reported
diabetes in questionnaires in the fourth (1994–1995), fifth (2001–
2002) and sixth (2007–2008) surveys of the Tromsø Study, through
elevated HbA1c (.6.5%) in one of the two former health surveys,
by linkage of the fourth survey participant list to the University
Hospital of North Norway digital discharge diagnosis registry
(ICD-9 codes 250, 357.2, 362.0, 583.8, 648.0, 648.8, 790.2, ICD-
10 codes E10.0–E14, O24 and R73) in conjunction with the
concurrent CVD registration, or by linkage to the Causes of Death
Registry. In addition, we did systematic manual and electronic
searches through medical charts for diabetes (before 2001 paper,
from 2001 digital records) on all participants registered with the
following cardiovascular diagnose codes in the International
Classification of Diseases version 9 and 10: ICD-9 codes 410–
414 (ischemic heart disease), 427 (cardiac dysrhythmia), 430–438
(cerebrovascular disease), 798 (sudden death) and 799 (other ill-
defined and unspecified causes of mortality), and ICD-10 codes
I20–I25 (ischemic heart disease), I47 (paroxysmal tachycardia), I47
(atrial fibrillation and flutter), I60–I69 (cerebrovascular disease),
R96 (other sudden death, cause unknown) and R98 (unattended
death) and R99 (other ill-defined and unspecified causes of
mortality). Cases of diabetes registered by means of one of these
procedures were verified by medical record information at the
University Hospital of North Norway, the only local hospital
serving the Tromsø population. Cases of unknown type of diabetes
were not included in the analyses, and only cases of verified
T2DM were used. Differentiation between type 1 and type 2
diabetes mellitus was based on clinical judgement and on
measurements of C-peptide and/or glutamic acid decarboxylase
antibody (anti-GAD). The T2DM endpoints were included till the
end of 2008 [17].
Definition of MI endpoints
Hospitalized cases of incident MI were identified by linking the
Tromsø Study participant list to the discharge diagnosis register at
the University Hospital of North Norway. To identify all possible
first-ever MI cases, our search strategy included the following
diagnostic codes: from 1980–98 ICD 9 codes 410–414 and 798–
7998; and thereafter ICD 10 codes I20–I25, and R96 and R98–
99. As for diabetes, we also systematically searched medical
Table 1. Event flow in the Tromsø study relevant for the present study.
Time point Event in Tromsø study Subjects (n) Relevant examinations
Included in present SNP
study (n)
1994–1995 4th survey first visit 27 158 Health questionnaire 9471
Physical examination 9471
Blood clot 9471
Serum lipids 9471
4th survey second visit 7965 HbA1c 4613
Serum 25(OH)D 4567
2001–2002 5th survey 8130 Serum PTH 3809
2007–2008 6th survey 12 984
31. Dec 2007 Cut off point for MI 2025
31. Dec 2008 Cut off point for T2DM 1092
Cut off point for cancer 2924
31. Dec 2010 Cut off point for mortality 3828
doi:10.1371/journal.pone.0037295.t001
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records for MI in participants registered with ICD-9 codes 427,
430–438, and 798–799, and ICD-10 codes I47–48, I60–I69, R96
and R98–99. The hospital medical record was then retrieved for
case validation. Discharge letters from hospitalizations in other
hospitals were also collected when appropriate. Further, the
Tromsø Study participant list was linked with the nationwide
Causes of Death Registry at Statistics Norway and the death
certificates were retrieved for those with an underlying or
contributing diagnosis of CVD or sudden unexpected death.
Relevant information was collected from additional sources such
as autopsy reports and records from nursing homes, ambulance
services and general practitioners. This procedure identified fatal
Table 2. Characteristics of the study population in 1994–1995.
Entire Tromsø
study cohort
Present
study
cohort Control cohort
Subjects with
endpoint MI
Subjects with
endpoint T2DM
Subjects with
endpoint cancer Dead
N 27 158 9471 4175 2025 1092 2924 3828
Males (%) 47.4 47.3 43.3 64.8 52.0 48.1 51.6
Current smokers (%) 36.1 33.3 26.1 35.1 28.4 35.3 34.1
Age (years) 46.9615.1 59.6613.7 65.6612.5 64.5612.1 60.2612.4 59.0613.8 67.2612.5
Systolic BP (mmHg) 134.8620.5 145.1623.8 149.2624.8 151.7624.4 152.2623.5 142.9623.4 152.5625.4
Diastolic BP (mmHg) 78.1612.4 83.0613.4 83.9613.8 86.1613.9 86.5613.7 82.0613.1 85.2614.5
BMI (kg/m2) 25.263.9 26.064.2 25.964.1 26.664.0 29.064.8 25.764.1 26.064.3
Total cholesterol (mmol/L) 6.0561.31 6.5961.32 6.7061.33 6.9461.29 6.6961.22 6.4361.31 6.7061.34
HDL cholesterol (mmol/L) 1.5060.41 1.5260.43 1.5460.44 1.3960.40 1.3360.38 1.5260.42 1.5160.45
Triglycerides (mmol/L) 1.5561.05 1.7061.09 1.6861.07 1.9961.20 2.3961.55 1.6161.01 1.7561.09
HbA1c (%)* 5.4560.66 5.5360.72 5.5160.74 5.6360.87 6.3661.45 5.5060.63 5.6460.86
25(OH)D (nmol/L)* 58.9620.1 58.4620.1 57.4619.8 58.6619.9 53.4618.5 62.8621.1 58.2620.6
*Measured only in those attending the second visit of the Tromsø study 1994–1995.
doi:10.1371/journal.pone.0037295.t002
Table 3. Genotype frequency and serum 25(OH)D levels in relation to genotype in the entire cohort.
Nearest gene SNP Genotype Frequency Serum 25(OH)D (nmol/L)** P (trend)***
major/minor major and
homyzygote minor Major Heterozygote Minor
homozygote* homozygote homozygote
GC rs2282679 TT/GG 0.56, 0.06 60.4620.3 56.2619.5 52.7618.8 ,0.001
rs7041 CC/AA 0.30, 0.20 61.4620.3 57.7620.0 55.4619.4 ,0.001
rs1155563 TT/CC 0.50, 0.08 60.2620.1 57.1620.0 52.9618.5 ,0.001
rs3755967 CC/TT 0.56, 0.06 60.5620.3 56.3619.5 53.0619.0 ,0.001
rs17467825 AA/GG 0.56, 0.06 60.5620.3 56.3619.6 52.8618.9 ,0.001
rs2298850 GG/CC 0.58, 0.06 60.3620.3 56.2619.5 52.5619.0 ,0.001
rs222020 TT/CC 0.69, 0.03 58.0620.2 59.2620.0 58.3619.6 ns
CYP2R1 rs10741657 GG/AA 0.34, 0.17 57.4620.3 58.6619.8 59.7620.7 0.001
rs2060793 GG/AA 0.34, 0.17 57.3620.2 58.6619.7 59.6620.7 0.001
rs12794714 GG/AA 0.35, 0.16 58.8620.8 58.8619.9 56.5619.2 0.001
rs1562902 TT/CC 0.30, 0.21 58.3620.0 58.2620.1 58.9620.3 ns
NADSYN1 rs12785878 TT/GG 0.38, 0.15 59.1620.4 58.2620.2 57.3619.1 ,0.05
rs3794060 TT/CC 0.38, 0.16 59.2620.4 58.1620.2 57.2619.1 ,0.05
rs3829251 GG/AA 0.54, 0.08 58.8620.3 58.3620.1 55.9619.0 ns
rs11234027 GG/AA 0.54, 0.08 58.8620.2 58.2620.0 56.2619.1 ns
CYP24A1 rs6013897 TT/AA 0.59, 0.06 59.2620.0 57.2619.8 56.5621.8 ,0.001
rs2762939 GG/CC 0.54, 0.07 59.0620.5 57.8619.4 56.7621.0 ns
*Analyzed in the entire cohort of 9471 subjects;
**analysed in 4567 subjects;
***P, linear trend across genotypes with gender, age, BMI, vitamin D/cod liver oil supplementation and season as covariates.
doi:10.1371/journal.pone.0037295.t003
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incident cases of MI that occurred as out-of-hospital deaths,
including deaths occurring outside Tromsø. Cases meeting
diagnostic criteria for definite or probable fatal or non-fatal first-
ever MI were classified as MI. WHO MONICA/MORGAM
criteria were used in the algorithms and included clinical
symptoms and signs, findings in electrocardiograms, values of
cardiac biomarkers and (when applicable) autopsy reports [18].
Silent MIs as defined by ECG only were not included as cases
because of difficulties in determining the exact date of the event.
The MI endpoints were included till the end of 2007.
Definition of cancer and mortality endpoints
Information on cancer incidence and cancer location was
retrieved from the Cancer Registry of Norway updated till the
end of 2008. Information on death was obtained from the Causes
of Death Registry, and information on moving out of the
Tromsø area and emigration from Norway was obtained from
the Norwegian Registry of Vital Statistics updated till the end of
2010.
Selection of study cohort and power calculation
In addition to MI, T2DM, endpoint registers for stroke, hip and
radial fractures, and aortic stenosis have been created as part of
the Tromsø study. When the subjects for the present study were
selected in December 2010, 1874 subjects were registered with MI,
1136 with T2DM, 1150 with stroke, 754 with hip fracture, 1177
with radial fracture, 569 with aortic stenosis, 2932 with cancer and
3850 were dead. In addition, 769 subjects with a total carotid
plaque area in the upper quartile in the carotid ultrasound
measurement at the second visit of the fourth survey were included
as cases. As all of these endpoints were of potential interest
regarding genetic polymorphisms, and limited funding did not
allow DNA preparation and genetic analyses of the entire Tromsø
Study cohort, we decided on a case-cohort design. With this
approach, the same ‘‘control cohort’’, randomly selected from the
entire cohort who attended the fourth survey in 1994–1995, could
be used as ‘‘control group’’ for all the different endpoints [19].
In the power calculation for deciding the size of the control
cohort, we assumed a difference in serum 25(OH)D of 20 nmol/L
between those with the most favourable and unfavourable
genotype [13], that this difference would result in a difference in
relative risk of approximately 1.3 regarding MI [20], and that 20%
of the controls had the exposed polymorphism. With these
assumptions and a= 0.05 including 3655 controls and 1218 cases
would give a power of 0.9 to detect a difference between genotypes
for MI. We therefore decided on a control cohort of 4000 subjects,
but included additional subjects in case some of the genetic
analyses or the DNA extractions were unsuccessful. The registra-
tion and quality control of endpoints continued until August 2011
and the final numbers of subjects with endpoints were therefore
different from when the subjects for DNA analyses were selected.
Measurements
At the survey in 1994–1995, the participants filled in
questionnaires on medical history, and lifestyle factors. Blood
pressure, height and weight, serum total cholesterol and triglyc-
erides were analyzed as previously described [15].
Sera from the second visit were stored at 270uC, and after a
median storage time of 13 years, thawed in March 2008 and
analyzed for 25(OH)D using an automated clinical chemistry
analyser (Modular E170, Roche DiagnosticsH, Mannheim,
Germany) [21].
In the first visit whole blood was collected for preparation of
blood clots that were later stored at the HUNT/NTNU Biobank
in Levanger, Mid-Norway where the DNA was also prepared
using a manual isolation method based on Clotted Lysate
Preparation Protocol for 8 or 16 samples on the Autopure LS
Instrument from Gentra (Gentra Systems Inc. MN, US) using
reagents from Qiagen (Qiagen NV, Venlo, The Netherlands).
In the fifth survey in the Tromsø study in 2001–2002 serum
parathyroid hormone (PTH) was measured conclusively as
previously described [22] and included in the present study as
an established marker of vitamin D’s biological effect [1].
Based on available data from two genome-wide association
studies [13,14], and one comprehensive association analysis [23],
17 SNPs located at or near the following genes with importance
for vitamin D metabolism and reported to be the most strongly
associated with the serum 25(OH)D levels, were selected for
analysis in the present study:
– The vitamin D binding protein (DBP) gene (DBP or GC): the six
top SNPs according to Wang et al. [13] (rs2282679, rs7041,
rs1155563, rs3755967, rs17467825, rs2298850) and one
additional promising SNP reported by Bu et al. [23]
(rs222020).
– The 25-hydroxylase gene (CYP2R1) involved in the conversion
of vitamin D into 25(OH)D: the top three SNPs according to
Wang et al. [13] (rs10741657, rs2060793, rs12794714
(rs1993116 probably proxy for rs2060793 and not included)),
and one additional promising SNP reported by Bu et al. [23]
(rs1562902).
– The 7-dehydrocholesterol reductase/NAD synthetase 1 gene
(NADSYN1) responsible for the availability of 7-dehydrocholes-
terol in the skin: the top two SNPs according to Wang et al.
[13] (rs12785878, rs3794060) and the two top SNPs according
to Ahn et al. [14] (rs3829251, rs11234027).
– The 24-hydroxylase gene (CYP24A1) involved in the degrada-
tion of 25(OH)D: rs6013897 [13]. Rs2762939 is not related to
the serum 25(OH)D level, but was still included because of a
potential relation to artery calcification [24], which could be
relevant in the present study.
All genotyping was performed by KBioscience (http://www.
kbioscience.co.uk) using KASP (KBioScience Allele-Specific
Polymorphism) SNP genotyping system. KASP is a competitive
allele-specific PCR incorporating a FRET (Fluorescence Reso-
nance Energy Transfer) quencher cassette. The KASP reporting
system is comprised of the following constituent oligonucleotides:
– Two allele-specific primers (one for each SNP allele). Each
primer contains a unique unlabelled tail sequence at its 59 end.
– One common (reverse) primer.
– Two 59 fluor-labelled oligonucleotides, one labelled with FAM,
one with HEX. These oligonucleotide sequences are designed
to interact with the sequences of the tails of the allele-specific
primers.
– Two further oligonucleotides, with quenchers bound at their 39
ends. These oligonucleotide sequences are complementary to
those of the fluor-labelled oligonucleotides (and therefore also
complementary to the tails of the allele-specific primers). These
quenched oligonucleotides therefore bind their fluor-labelled
complements and all fluorescent signal is quenched until
required.
In the initial stage of PCR, the appropriate allele-specific primer
binds to its complementary region directly upstream of the SNP
(with the 39 end of the primer positioned at the SNP nucleotide).
The common reverse primer also binds and PCR proceeds, with
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the allele-specific primer becoming incorporated into the template.
During this phase, the fluor-labelled oligonucleotides remain
bound to their quencher-bound complementary oligonucleotides,
and no fluorescent signal is generated.
As PCR proceeds, one of the fluor-labelled oligonucleotides
corresponding to the amplified allele also gets incorporated into
the template and is hence no longer bound to its quencher-bound
complement. As the fluor is no longer quenched, the appropriate
fluorescent signal is generated and detected by the usual means. If
the genotype at a given SNP is homozygous, only one or other of
the possible fluorescent signals will be generated. If the individual
is heterozygous, the result will be a mixed fluorescent signal.
In all genotyping plates no-template controls (NTCs) are
included to demonstrate that any amplification in the sample
wells is due solely to the presence of the sample DNA. Two
separate manual quality control checks are performed, and the
data is also checked by specific software to determine that there
are no incorrect call assignments, no samples too close or too far
from the origin, no NTCs amplified, or any incorrect calls.
Statistical analyses
The relation between SNP genotypes and the endpoints MI,
T2DM, cancer and mortality were evaluated in Cox regression
analyses with age, gender, body mass index (BMI), and vitamin D/
cod liver oil supplementation as covariates. For MI the risk factors
systolic blood pressure and serum cholesterol were included as well
in a separate analysis to examine if relations could be explained
through these risk factors. For mortality, the observation time was
set from 1994, for the other endpoints from birth. The period of
observation was cut off by the end of 2007 for MI, 2008 for
diabetes and cancer, and 2010 for mortality. The predefined
control cohort was used as controls for the subjects with a specific
endpoint (cases). Since this control cohort was randomly selected
from the entire cohort, it also included a considerable number of
subjects with one or more endpoints. When analyzing a specific
endpoint, subjects in the control cohort with that specific endpoint
were moved to the case group (which only included subjects with
that specific endpoint). Therefore, the size of the control cohort
varied depending on endpoint in question. Because of the size of
the control-cohort, we did not make adjustment to the partial
likelihood in the Cox regression analyses [19].
Distribution of the continuous variables serum 25(OH)D, blood
pressure, lipids, BMI and HbA1c was evaluated for skewness and
curtosis and visual inspection of histograms and found normal
except for triglycerides, HbA1c and PTH which were normalized
by log transformation before use as dependent variables. Trends
across the genotypes were evaluated with linear regression with
age, gender, BMI, month of examination (with the use of dummy
variables) and intake of vitamin D supplements or cod liver oil as
covariates. The CVD risk factors were evaluated within the entire
cohort.
The genotype frequencies were examined for compliance with
Hardy-Weinberg equilibrium using chi-squared analysis [25].
Linkage disequilibrium (LD) between SNPs was evaluated with r2
and Lewontin’s D9 statistics [26,27].
Based on the b coefficients from regression analyses with serum
25(OH)D as dependent variable, the risk alleles (the ones
associated with low serum 25(OH)D levels) were weighted and a
genotype score constructed [13]. For this score only SNP
significantly related to the serum 25(OH)D levels were included,
and only SNPs that were uncorrelated (r2,0.40) [28]. In the Cox
regression analyses the cohort was divided in genotype score
Table 4. Number of subjects with specific endpoints and number of subjects in corresponding control groups and hazard ratio
with 95% confidence interval in relation to genotype score quartile and genotypes in the four selected SNPs.
MI T2DM Cancer Death
Endpoint (n) 2025 1092 2924 3828
Controls (n) 3295 3785 3264 2379
Genotype score Quartile 1* ref ref ref ref
Quartile 2 1.10 (0.97–1.24) 1.09 (0.92–1.29) 1.04 (0.94–1.16) 1.05 (0.96–1.15)
Quartile 3 1.09 (0.96–1.23) 1.02 (0.86–1.20) 1.02 (0.92–1.13) 1.03 (0.94–1.13)
Quartile 4 0.93 (0.82–1.06) 1.01 (0.86–1.20) 0.96 (0.87–1.07) 1.01 (0.92–1.10)
rs2298850 Major homozygote ref ref ref ref
Heterozygote 0.91 (0.83–1.00) 0.98 (0.86–1.12) 0.98 (0.91–1.06) 0.95 (0.89–1.02)
Minor homozygote{ 0.83 (0.68–1.01) 0.87 (0.67–1.14) 1.01 (0.86–1.18) 0.97 (0.84–1.12)
rs10741657 Major homozygote{ ref ref ref ref
Heterozygote 1.05 (0.95–1.16) 1.07 (0.94–1.22) 1.03 (0.95–1.12) 1.04 (0.97–1.12)
Minor homozygote 1.05 (0.92–1.19) 1.00 (0.83–1.19) 1.03 (0.92–1.14) 0.98 (0.89–1.08)
rs3794060 Major homozygote ref ref ref ref
Heterozygote 1.03 (0.94–1.14) 0.99 (0.87–1.13) 1.00 (0.92–1.08) 1.04 (0.97–1.11)
Minor homozygote{ 1.00 (0.88–1.15) 0.99 (0.82–1.18) 0.94 (0.84–1.05) 1.06 (0.96–1–17)
rs6013897 Major homozygote ref ref ref ref
Heterozygote 1.09 (0.99–1.20) 1.07 (0.95–1.22) 1.02 (0.94–1.10) 1.05 (0.98–1.12)
Minor homozygote{ 1.11 (0.92–1.34) 1.13 (0.88–1.47) 1.20 (1.03–1.41) 1.05 (0.92–1.21)
Cox regression with adjustment for age, gender, BMI and vitamin D/cod liver oil supplementation. None of the relations for the individual SNPs remained statistically
significant after correction for multiple comparisons with a factor of 32.
*Quartile with highest serum 25(OH)D level.
{Risk allele.
doi:10.1371/journal.pone.0037295.t004
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quartiles with the lowest quartile (the one with the highest serum
25(OH)D level) as reference. In addition, the individual SNPs were
also evaluated in the Cox regression with the major homozygote
genotype used as reference.
The data are shown as mean 6 SD. All tests were done two-
sided, and a P-value,0.05 was considered statically significant.
Where the individual SNPs were analyzed, corrections for multiple
testing were performed with the Bonferroni method. Thus, in the
Cox regression analyses the P-values were multiplied by a factor of
32 (4 SNPs and 8 endpoints) and for the relation between CVD
risk factors and SNPs with a factor of 4.
Ethics
The study was approved by the Regional Committee for
Medical and Health Research Ethics (REK nord) (reference 2010/
2913-4). Only participants with valid written consent were
included.
Results
A total of 9528 subjects were selected for participation in the
study and DNA successfully prepared and analyzed for at least one
SNP in 9471 subjects. Among these, 4175 were included as control
cohort, 2025 subjects were finally registered with the endpoints
MI, 1092 with T2DM, 2924 with cancer and 3828 had died
(Table 1). The age distribution, gender, smoking habits and
laboratory data from 1994–1995 in these subjects are shown in
Table 2. The genotypes for all the SNPs were in Hardy-Weinberg
equilibrium in all analyses except for the four SNPs at the
NADSYN1 gene where chi-squared testing gave P,0.05.
The individual SNP analyses were successful in 98.8–99.5% of
the subjects. The serum 25(OH)D levels in relation to genotype are
shown in Table 3. In general, the mean differences in serum
25(OH)D between the major and minor homozygote genotypes
were for SNPs related to the GC, CYP2R1, NADSYN1 and
CYP24A1 genes 0.3–7.8 nmol/L, 0.6–2.4 nmol/L, 1.8–2.9 nmol/
L, and 2.3–2.7 nmol/L, respectively.
The SNPs with the same gene location, and that in addition
were significantly related to serum 25(OH)D levels, were highly
correlated. Thus, for the GC gene, rs2298850, which was the SNP
with the highest difference in mean serum 25(OH)D between
major and minor homozygotes, was in LD with rs2282679,
rs1155563, rs3755967, rs17467825 (r2 = 0.90, 0.59, 0.92, 0.92,
respectively), but not with rs7041 (r2 = 0.38). Similarly, for the
CYP2R1 gene, rs10741657 was in LD with rs2060793 and
rs12794714 (r2 = 1.00 and 0.49, respectively), and for the
NADSYN1 gene rs3794060 was in LD with rs12785878
(r2 = 1.00). However, none of the SNPs rs2298850, rs7041,
rs10741657, rs3794060 and rs6013897 was in LD with each
other, and these five SNPs were used for construction of the
genotype score. The mean serum 25(OH)D levels in the four
quartiles of this genotype score were 62.5620.7, 59.1619.8,
57.3619.5 and 54.7619.5 nmol/L, respectively.
In the Tables 4 and 5 the results regarding the endpoints in
relation to these genotype score quartiles together with the four
SNPs selected because of significant and highest difference in
serum 25(OH)D between major and minor homozygotes within
each gene, are presented.
The genotype score was not related to serum PTH, but
rs6013897 located at the CYP24A1 gene showed a significant
Table 5. Number of subjects with specific types of cancer and number of subjects in corresponding control groups and hazard
ratio with 95% confidence interval in relation to genotype score quartile and genotypes in the four selected SNPs.
Breast cancer Lung cancer Colorectal cancer Prostate cancer
Endpoint (n) 403 312 438 375
Controls (n) 2273 4066 3996 1665
Genotype score Quartile 1** ref ref ref ref
Quartile 2 1.14 (0.85–1.52) 0.89 (0.65–1.23) 0.92 (0.70–1.22) 1.11 (0.84–1.48)
Quartile 3 1.18 (0.89–1.56) 0.99 (0.73–1.35) 1.13 (0.87–1.47) 1.15 (0.86–1.53)
Quartile 4 1.11 (0.83–1.47) 0.87 (0.64–1.18) 1.06 (0.82–1.38) 0.99 (0.75–1.32)
rs2298850 Major homozygote ref ref ref ref
Heterozygote 1.01 (0.82–1.24) 0.92 (0.72–1.16) 1.07 (0.88–1.31) 1.13 (0.91–1.40)
Minor homozygote{ 0.84 (0.51–1.39) 1.12 (0.71–1.77) 1.44 (1.01–2.07) 1.19 (0.80–1.78)
rs10741657 Major homozygote{ ref ref ref ref
Heterozygote 1.13 (0.91–1.41) 0.89 (0.70–1.13) 0.99 (0.80–1.22) 1.15 (0.91–1.45)
Minor homozygote 0.96 (0.71–1.29) 0.82 (0.58–1.14) 1.02 (0.78–1.34) 1.19 (0.89–1.61)
rs3794060 Major homozygote ref ref ref ref
Heterozygote 1.02 (0.83–1.27) 0.83 (0.65–1.05) 0.86 (0.70–1.05) 0.91 (0.73–1.14)
Minor homozygote{ 0.95 (0.71–1.29) 0.97 (0.70–1.35) 0.73 (0.54–0.99) 0.88 (0.64–1.21)
rs6013897 Major homozygote ref ref ref ref
Heterozygote 1.22 (1.00–1.50) 0.91 (0.72–1.16) 1.05 (0.85–1.28) 0.95 (0.76–1.18)
Minor homozygote{ 1.86(1.28–2.70)* 1.02 (0.62–1.67) 1.29 (0.87–1.91) 1.10 (0.69–1.73)
*P,0.05; Cox regression with adjustment for age, gender, BMI and vitamin D/cod liver oil supplementation. Correction for multiple comparisons for the individual SNPs
was performed with a factor of 32.
**Quartile with highest serum 25(OH)D level.
{Risk allele.
doi:10.1371/journal.pone.0037295.t005
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relation with lower mean serum PTH level for the polymorphism
with the highest mean serum 25(OH)D level (Table 6).
Major endpoints
Neither the genotype score nor any of the four selected SNPs
were significantly associated with MI, T2DM, cancer and
mortality after correction for multiple testing (Table 4). For MI
inclusion of the risk factors systolic blood pressure and serum
cholesterol did not affect these results (data not shown). When
cancer was subdivided according to location (breast, lung,
colorectal and prostate), rs6013897 at the CYP24A1 gene showed
a significant relation with breast cancer (P,0.05) where the minor
homozygote, which was the one with the lowest serum 25(OH)D
level, had an 86% higher risk of developing breast cancer than the
major and reference homozygote (Figure 1). This was the only one
of the four selected SNPs, as well as the genotype score, that
showed a significant relation to a specific cancer.
CVD risk factors
There was no significant relation between CVD risk factors and
the genotype score or the four selected SNPs (Table 6). There was
no difference in smoking habits in relation to any of the SNP
genotypes (data not shown).
Discussion
To our knowledge, this is the first large population based study
where SNPs associated with the serum 25(OH)D levels have been
reported in relation to the major diseases CVD, T2DM, cancer,
mortality, and risk factors for disease. As expected we found a
significant relation between the selected SNPs and serum
25(OH)D levels [13,14], whereas the relations with the hard
endpoints and CVD risk factors were not consistent.
Table 6. CVD risk factors in 1994–1995 and serum PTH in 2001–2002 in relation to genotype score quartile and genotypes in the
four selected SNPs in the entire study cohort of 9471 subjects.
SNP and genotypes
Systolic blood
pressure (mmHg) BMI (kg/m2)
Total cholesterol
(mmol/L)
Tri-glycerides
(mmol/L) HbA1c (%)**
Serum PTH
(pmol/L)***
Genotype score Quartile 1**** 145.5624.3 26.064.2 6.5661.33 1.7061.11 5.5560.83 3.6461.97
Quartile 2 144.9623.6 26.164.2 6.5961.32 1.7061.01 5.5360.67 3.7161.95
Quartile 3 145.0623.7 25.964.3 6.6361.33 1.6861.10 5.5360.71 3.6861.74
Quartile 4 144.9623.7 25.964.1 6.5861.31 1.7261.15 5.5360.69 3.7861.91
rs2298850 Major homozygote 145.3624.0 26.064.2 6.5861.33 1.7061.08 5.5560.75 3.7361.99
Heterozygote 144.6623.6 25.964.1 6.6061.32 1.6861.09 5.5160.69 3.6561.72
Minor homozygote{ 146.0623.9 25.963.9 6.5761.32 1.7561.17 5.5160.63 3.6761.87
rs10741657 Major homozygote{ 144.3623.3 25.964.1 6.5761.34 1.7061.12 5.5360.68 3.7661.96
Heterozygote 145.7623.9 26.164.2 6.6061.31 1.7161.09 5.5360.73 3.6661.83
Minor homozygote 144.9624.5 25.964.2 6.5861.32 1.6561.02 5.5460.79 3.6961.93
rs3794060 Major homozygote 144.7623.8 26.064.2 6.5661.32 1.6761.06 5.5660.83 3.6361.76
Heterozygote 144.9623.5 26.064.1 6.5961.32 1.7261.11 5.5260.67 3.7462.00
Minor homozygote{ 146.5624.8 26.064.2 6.6261.33 1.7161.12 5.5260.60 3.7961.88
rs6013897 Major homozygote 145.0624.0 25.964.1 6.6061.31 1.7261.10 5.5260.71 3.5661.87*
Heterozygote 145.2623.5 26.064.2 6.5761.34 1.6761.09 5.5460.75 3.8861.96
Minor homozygote{ 145.2623.7 26.164.3 6.5961.27 1.7361.04 5.5760.71 3.9861.79
*P,0.05 for linear trend across genotype, linear regression with gender, age, BMI, vitamin D/cod liver oil supplementation and season as covariates. Correction for
multiple comparisons for the individual SNPs was performed with a factor of 5.
**Analyzed in 4613 subjects;
***Analyzed in 3809 subjects in the fifth survey in 2001–2002.
****Quartile with highest serum 25(OH)D level.
{Risk allele.
doi:10.1371/journal.pone.0037295.t006
Figure 1. Cumultative probability of first breast cancer
according to rs6013897 genotypes based on Cox regression
with age and BMI as covariates.
doi:10.1371/journal.pone.0037295.g001
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The SNPs analysed by us are all involved in important steps in
vitamin D metabolism like availability of substrate for vitamin D
production in the skin (NADSYN1 gene), hydroxylation to
25(OH)D (CYP2R1 gene), transport of 25(OH)D in the circulation
(DBP or GC gene) and degradation to inactive metabolites
(CYP24A1 gene) [13]. The SNPs are not influenced by life-style,
and their effects are life-long. Accordingly, they may potentially be
better markers of a subject’s vitamin D status than a single serum
25(OH)D measurement. Although no substitute for RCTs, the
identification of these SNPs has made it possible to indirectly test
the relation between serum 25(OH)D and diseases. In particular,
one could expect to see a relation with diseases that develop over a
long period of time like CVD, T2DM, cancer and ultimately also
death.
Regarding mortality, where a low serum 25(OH)D level is a
predictor [7,9], all hazard ratios were close to 1.00 with no trend
for the low genotype score, nor the individual genotypes associated
with high serum 25(OH)D levels, to have a protective effect.
Similarly, low serum 25(OH)D is a predictor of MI [29], but none
of the genotypes for the SNPs examined appeared related to MI
risk. This was not changed by inclusion of the risk factors systolic
blood pressure and serum cholesterol in the Cox regression
analyses. Although not statistically significant, it was also
noteworthy that for rs2298850 (which was the SNP with the
highest difference between major and minor homozygotes
regarding serum 25(OH)D)) there was 17% reduced risk of MI
for the genotype with the lowest serum 25(OH)D level. An
association between SNPs in the CYP24A1 gene and MI could
have been expected as Sehn et al. [24] reported one such SNP
(rs2762939) to be related to coronary artery calcification, which
again predicts CVD [30]. However, none of the CYP24A1 gene
SNPs, (including rs2762939) appeared related to MI in our cohort.
A relation between vitamin D and cancer is plausible as VDR,
which is a nuclear receptor, is found in cells in a number of tissues
and the active form of vitamin D, 1,25-dihydroxyvitamin D
(1,25(OH)2D), appears to have anti-proliferative effects [31].
Epidemiological data indicate a negative prognostic role for low
serum 25(OH)D levels regarding cancer [32], but so far a cause-
and-effect relationship has not been established [33]. In line with
this, for the genotype score quartiles and most of the SNPs
analyzed by us the hazard ratios for cancer were close to 1.00
except for rs6013897. For this SNP the genotype associated with
the lowest serum 25(OH)D level had a 20% increased risk of
cancer, but this was not significant after adjustment for multiple
comparisons.
As our cohort included as many as 2924 cases with cancer, we
also investigated breast, colorectal, lung and prostate cancer
separately. For lung cancer [34] as well as for prostate cancer [35]
there are only weak indications for a relation with vitamin D, and
neither for the genotype score quartiles nor the SNPs analyzed by
us were there any significant associations. For breast cancer, the
situation is similar with no consensus on whether serum 25(OH)D
is predictive of future disease or not [36]. However, for the SNP
rs6013897, subjects with the minor homozygote genotype (which
was the one with the lowest serum 25(OH)D level), had almost
twice the risk of developing breast cancer as compared to subjects
with the major homozygote genotype.
The rs6013897 is related to the CYP24A1 gene which is
considered as an oncogene. This gene (the 24-hydroxylase
enzyme) converts 25(OH)D as well as 1,25(OH)2D to their
inactive forms and is present also in peripheral tissues. Locally
produced 1,25(OH)2D is assumed to have an anti-cancer effect,
and an increased local expression of the CYP24A1 gene (and
thereby increased degradation of 1,25(OH)2D) has been associated
with poor survival [37]. It is therefore reasonable that also
polymorphisms in this gene may affect risk of cancer. However,
Anderson et al. [38] who examined 1560 subjects with breast
cancer and 1633 controls found no relation between SNPs in
CYP24A1 gene and breast cancer, whereas they reported an
association between breast cancer and rs7041 which was not seen
in our study (data not shown). And to add to the confusion, in a
study from China including 2919 cases and 2323 controls, neither
rs7041 nor rs2762932 (proxy for rs6013897) were considered
significantly related to breast cancer [39].
For colorectal cancer there appears to be an inverse relation
with intake of vitamin D as well as with serum 25(OH)D levels
[40]. However, RCT evidence is limited, and none of the SNPs
examined by us, or the genotype score, showed a significant
association with colorectal cancer. Similar to the other endpoints,
there was no consistent trend for a protective effect of genotypes
associated with high serum 25(OH)D levels.
The cross-sectional associations between serum 25(OH)D levels
and risk factors for disease like blood pressure, BMI, serum lipids
and HbA1c are undisputable. From our own studies we have found
the unadjusted mean difference between the lower and higher
quartiles of serum 25(OH)D to be 7.7 mmHg for systolic blood
pressure, 1.4 kg/m2 for BMI, 0.08% for HbA1c and 0.37 mmol/L
for TG [2–5]. These relations with risk factors could possibly
explain the association between serum 25(OH)D levels and CVD
[29], T2DM [6,8] and mortality [9]. However, after correction for
multiple testing no significant findings regarding SNPs and CVD
risk factors were found. On the other hand, we did find a
significant relation for rs6013897 where the genotype with the
highest serum 25(OH)D level had the lowest serum PTH level,
indicating at least some physiological importance for that SNPs in
calcium metabolism.
There could be a number of reasons why we were not able to
disclose the presumed relations between the SNPs and health. First
of all, the mean differences between the genotypes with the highest
and lowest serum 25(OH)D levels, and also between the first and
fourth genotype score quartiles, were no more than 8 nmol/L.
This was substantially lower than that reported by Wang et al. who
found differences of 18 nmol/L in the Framingham Heart Study
and 13 nmol/L in the 1958 British Birth Cohort [13]. In the
power calculations we therefore assumed a greater difference in
serum 25(OH)D levels than what we actually found. We also made
the calculations based on cross-sectional and longitudinal associ-
ations between serum 25(OH)D levels and diseases which may not
reflect causal relations. The power calculation may therefore have
been too optimistic, and the study underpowered. Secondly, for
SNPs at the NADSYN1 gene the population was not in Hardy-
Weinberg equilibrium and the results for that gene may therefore
have been biased. This could possibly be explained by the high
proportion of the Tromsø population having Sami ancestry [41] as
SNPs in the NADSYN1 gene show a remarkable difference in allele
frequency at least between Asian and Western populations [42].
Unfortunately, we did not have any ancestry-informative SNPs
that could verify this hypothesis.
Furthermore, the SNPs with the greatest difference between
genotypes were related to the DBP gene. These same polymor-
phisms are strongly related to the concentration of DBP [13], and
the serum 25(OH)D assays used today measure total 25(OH)D
and not only the free fraction. Presumably it is the free fraction of
25(OH)D that is the biologically active, and changes in the total
amount of 25(OH)D induced by changes in the DBP concentra-
tion might therefore be misleading. Also, if the SNP-induced
changes in amount of DBP are accompanied by changes in affinity
between binding protein and 25(OH)D, the differences in total
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25(OH)D will be even more difficult to interpret [43]. In addition,
the differences between the genotypes for the other SNP were
rather small, and no greater than 3 nmol/L. Accordingly, it would
for these SNPs be very difficult to disclose an effect on hard
endpoints as well as risk factors. And finally, one may speculate
that an effect of small differences in serum 25(OH)D, as those
induced by the SNPs in our study, would be most evident in a
vitamin D depleted population. Although Tromsø is located far
North (at 69uN), and the average serum 25(OH)D levels not
optimal, it was still not much different from what is seen in the rest
of Western Europe [29], and our results may therefore not apply
in areas of profound vitamin D deficiency.
The classical effect of vitamin D is increased intestinal calcium
absorption, and vitamin D deficiency leads to rickets in children
and osteomalacia and/or osteopenia in adults [1]. These relations
are well documented and it might be easier to document an effect
of vitamin D SNPs on the skeleton than on MI, T2DM, cancer
and mortality. It should also be noted that even if a consistent
relation between SNP genotypes and disease had been found, that
would only have been an indication of causality and no proof.
Thus, the SNPs could very well be associated with other genes that
were the ones truly causing the observed effect, and the vitamin D
SNPs therefore only markers of disease risk.
We analysed 17 SNPs known to be associated with the serum
25(OH)D level. For each of the four related genes we selected the
SNP with the highest difference in serum 25(OH)D between the
genotypes. Furthermore, we analyzed four hard endpoints and
also subdivided one of them, cancer, according to organ location.
Accordingly, we had to correct for multiple comparisons and the
P-values for the hard endpoints were corrected with the
Bonferroni method. However, even if we had used a less
conservative approach like correcting with a factor of four
(because of the number of SNPs pre-selected for analyzes), no
additional relations with the hard endpoints would have reached
statistical significance. Furthermore, in the principal analysis we
used a combined genotype score without correction of the P-value,
and still no significant associations with the end points were seen.
It must also be emphasised that our main hypothesis was that
genotypes associated with high serum 25(OH)D level would
‘‘protect’’ against disease. However, we found no such trend. In
this context it is worth mentioning that although the literature on
SNPs affecting the serum 25(OH)D level and health is sparse,
there is an abundance of such publications for SNPs in the VDR
gene [44]. These publications have shown very little consistency,
which may reflect that for normal biological effects of vitamin D,
polymorphisms characterised so far are of limited importance. On
the other hand, a significant relation between SNPs in the
CYP2R1, DHCR7 (NADSYN1) and CYP27B1 genes and predispo-
sition to type 1 diabetes have been reported [45], and genetic
polymorphisms in the vitamin D system may be more important in
the pathogenesis of autoimmune diseases than in the diseases
studied by us.
In addition to the number of shortcomings, our study also has
some strengths. The endpoint registers were carefully established
and quality checked, the number of subjects with endpoints was
substantial, and the study was population based. The case-cohort
study design used by us is also well suited if more than one
endpoint is to be evaluated [19].
In conclusion, we have not been able to document consistent
relations between SNPs associated with serum 25(OH)D levels and
MI, T2DM, cancer, mortality or CVD risk factors, with a possible
exception for rs6013897 and breast cancer. This does not exclude
that these SNPs contribute in the pathogenesis of MI, T2DM or
cancer, but makes it unlikely that they have a major influence.
Further studies are needed to evaluate these SNPs in relation to
other diseases, in populations with different genetic background, as
well as in vitamin D depleted populations.
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